K-PAX Pharmaceuticals is engaged in the development of products that support optimal mitochondrial function.

K-PAX Pharmaceuticals is a San Francisco Bay Area biopharma company focused on reversing the mitochondrial failure currently believed to trigger and promote the progression of several neurodegenerative diseases including Alzheimer's disease, Parkinson's disease, and ALS.

Our lead asset is KPAX002, is a mitochondrial support compound comprised of two components, both of which support and improve neuronal function.  The first component consists of a proprietary mitochondrial modulator well known to broadly support mitochondrial health and function. The second component consists of a currently available medication that, when augmented with mitochondrial support, can generate sustained improvement in cognitive function in patients with Alzheimer's and other neurodegenerative diseases.

We are currently pursuing several indications: 

1) Alzheimer's disease

2) Parkinson's disease

3) Amyotrophic Lateral Sclerosis (ALS)